A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

A seven-year study of 470 patients revealed that a severe fungal lung infection once mainly seen in specific high-risk groups ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

A new Gilead study shows that a single-tablet combo of HIV-fighting drugs could help patients who today take multiple drugs.

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. The efficacy of immune checkpoint inhibitors was ...

A 37-year-old HIV-positive man faced delays in appendectomy, being shuffled between hospitals, prompting an inquiry into ...